title: Immunosuppressant supplementation to infliximab in Crohn's disease with extraintestinal involvement: a benefit in the long term?
authors.forename: Mariabeatrice
authors.initials: M
authors.lastname: Principi
authors.forename: Enzo
authors.initials: E
authors.lastname: Ierardi
authors.forename: Daniela
authors.initials: D
authors.lastname: Antonicelli
authors.forename: Alberto
authors.initials: A
authors.lastname: Pastorelli
authors.forename: Antonio
authors.initials: A
authors.lastname: Pisani
authors.forename: Alfredo
authors.initials: A
authors.lastname: Di Leo
authors.forename: Carmine
authors.initials: C
authors.lastname: Panella
authors.forename: Antonio
authors.initials: A
authors.lastname: Francavilla
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy* / Q000473:pathology*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D012074:Remission Induction / Q000379:methods*; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D000069285:Infliximab